Contributor Disclosures for Pure Red Cell Aplasia

Role Name Disclosure Details Author  Paul Schick, MD, Emeritus Professor, Department of Internal Medicine, Thomas Jefferson University Medical College; Research Professor, Department of Internal Medicine, Drexel University College of Medicine Nothing to disclose Details Medical Editor  Rodger L Bick, MD, PhD, FACP, Clinical Professor of Medicine, University of Texas Southwestern Medical Center; Director, Dallas & Pacific Thrombosis Hemostasis Vascular Medicine Clinical Center Nothing to disclose Details Pharmacy Editor  Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine Nothing to disclose Details Managing Editor  Troy H Guthrie, Jr, MD, Director of Cancer Institute, Baptist Medical Center Nothing to disclose Details CME Editor  Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems Nothing to disclose Details Chief Editor  Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University Nothing to disclose Details CONTRIBUTOR DISCLOSURE FORM Contributor Name: Paul Schick  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Rodger L Bick, Medical Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Francisco Talavera  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Troy H Guthrie, jr, Managing Editor  The contributor discloses no conflict of interest.  Contributor Disclosure Contributor: Contributor Disclosure: Rajalaxmi McKenna, CME Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Emmanuel C Besa  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication Revlimid in non-5q- syndrome MDSExjade in transfusion overload in MDS